Guided Therapeutics (GTHP) Long-Term Investments (2025 - 2026)
Guided Therapeutics' (GTHP) quarterly Long-Term Investments came in at $557000.0 in Q2 2026, up 9.22% quarter-over-quarter from $510000.0 in Q1 2026.
Powered by 
Analysis
Guided Therapeutics (GTHP) Long-Term Investments (2025 - 2026) Analysis & Trends
Guided Therapeutics has disclosed Long-Term Investments across 2 years of filings, most recently posting $557000.0 for Q2 2026.
- In Q2 2026, Long-Term Investments changed N/A year-over-year to $557000.0; the TTM figure through Jun 2026 stood at $557000.0 (changed N/A YoY), while the FY2025 annual figure was $473000.0, changed N/A from the prior year.
- Long-Term Investments came in at $557000.0 for Q2 2026 at Guided Therapeutics, up from $510000.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $557000.0 in Q2 2026 to a low of $473000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 1.11 Bn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 3.41 Bn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | - |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 2.25 Bn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 244.10 Mn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | - |
| 9 | Steris | 21.90 Bn | 21.43 Bn | 684.20 Mn | - |
| 10 | Guided Therapeutics | 19.31 Mn | 19.30 Mn | - | 557,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 557,000.00 |
| Mar 31, 2026 | 510,000.00 |
| Dec 31, 2025 | 473,000.00 |